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1 These authors contributed equally to this work.Aurora B kinase (Aurora-B) functions in chromosome segregation and cleavage of polar spindle
microtubules. However, its role in cellular senescence remains elusive. Here, we investigated
Aurora-B effects on cellular senescence in human ﬁbroblasts and endothelial cells. Aurora-B levels
were reduced during replicative senescence and premature senescence by adriamycin. Aurora-B
overexpression in old cells partially reversed senescence phenotypes. In contrast, Aurora-B
down-regulation accelerated cellular senescence. p53 knockdown but not p16 knockdown inhibited
cellular senescence by Aurora-B reduction. These results suggest that Aurora-B might function in
the regulation of cellular senescence of human primary cells via a p53-dependent pathway.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cellular senescence is generally deﬁned as irreversible prolifer-
ation arrest [1], which contributes to tumor suppression, tumor
progression, tissue repair, age-related pathology, and tissue/organ-
ismal aging [2]. Cellular senescence is known to be induced by di-
verse factors, such as telomere erosion, strong mitotic signals,
activation of tumor suppressor genes, oxidative stress, chemother-
apeutic agents, and culture stress with or without a persistent DNA
damage response [3]. In addition to irreversible growth arrest,
senescent cells show a variety of phenotypes, including enlarged
and ﬂattened morphology, expression of senescence-associated b-
galactosidase (SA-b-gal) activity, up-regulation of p53 or p16INK4a
levels, formation of senescence-associated heterochromatic foci
and DNA damage foci in the nucleus, and secretion of inﬂammatory
molecules such as growth factors, proteases, cytokines, and chemo-
kines [4]. Although diverse factors and phenotypes are associated
with cellular senescence, two tumor suppressor pathways, the
p53 and pRB/p16INK4a pathways, are critically responsible for
the regulation of cellular senescence [5].
In addition, a variety of evidence suggests that down-regulation
or inhibition of several mitotic proteins, which play key roles in
centrosome and kinetochore integrity andmitotic checkpoint func-
tion, is sufﬁcient to activate a p53-mediated premature senescencechemical Societies. Published by Ephenotype [6]. Senescent cells show many chromosomal abnor-
malities due to mitotic dysregulation. Several genes involved in
the regulation of chromosomal processing and assembly, such as
CENP-A, CENP-F, mitotic kinesin-like protein-1, etc., were reported
to be altered in ﬁbroblasts isolated from old age humans and hu-
mans with progeria [7]. CENP-A protein levels were also found to
be reduced in senescent human ﬁbroblasts, and CENP-A knock-
down induced premature senescence through a p53-dependent
pathway [8]. Increased polyploidy has been observed in aortic vas-
cular smooth muscle cells [9], human diploid ﬁbroblasts [10], and
endothelial cells [11]. The levels of chromosome-speciﬁc aneu-
ploidy increases with the donor’s age [12]. These results suggest
that an underlying mechanism of the aging process involves
increasing errors in the mitotic machinery of cells due to altered
expression of mitotic genes.
Aurora kinases, a family of serine/threonine kinases, are impor-
tant regulators of mitosis in the progression from mitotic entry to
cytokinesis. Mammals have three Aurora kinases, Aurora A, B, and
C [13]. These proteins have important functions in centromosome
duplication, mitotic spindle assembly, chromosome condensation,
chromosome biorientation on the spindle, and chromosome segre-
gation [14]. Aurora A associates with spindle poles and regulates
entry into mitosis, centrosome maturation, and bipolar spindle for-
mation [13]. Aurora-B is a member of the Chromosomal passenger
complex (CPC), which transfers from the inner centromere in early
mitosis to the spindle midzone, equatorial cortex, and midbody
during late mitosis and cytokinesis [15]. Aurora-B also functions
in the promotion of chromosome bi-orientation by correctinglsevier B.V. All rights reserved.
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checkpoint activation, control of sister chromatids, dissolution of
centromeric cohesion, cleavage furrow ingression, and cytokinesis
during anaphase [16]. Since successful cell division depends on the
function of key regulatory protein kinases such as Aurora kinases,
defects in their function and expression result in aneuploidy, lead-
ing to tumorigenesis, apoptosis or senescence [16,17]. Aurora A
overexpression induces cellular senescence in mammary gland
hyperplastic tumors in p53-deﬁcient mice [18]. MLN8054, an
inhibitor of Aurora A kinase, induces senescence in human tumor
cells both in vitro and in vivo [19]. Inhibition of Aurora kinases
by VX-680 increases the Bax/Bcl-2 ratio and induces apoptosis in
Aurora A-high acute myeloid leukemia [20]. Exogenous introduc-
tion of Aurora-B in human BJ ﬁbroblast cells was shown to de-
crease cell growth and increase the SA-b-gal activity by
activation of p53 tumor suppressor [21]. Although Aurora kinases
play essential functions in the regulation of mitosis and thus con-
tribute to the determination of cell fates, much remains unknown
about how these kinases regulate cellular senescence in human
primary cells.
In the present study, we found that Aurora-B levels decreased in
senescent human dermal ﬁbroblasts and human umbilical vein
endothelial cells. Up-regulation of Aurora-B in senescent cells par-
tially reversed senescence phenotypes, and Aurora-B knockdown
accelerated premature senescence through a p53-dependent
pathway.
2. Materials and methods
2.1. Materials
Human dermal ﬁbroblasts (HDFs), human umbilical vein endo-
thelial cells (HUVECs), and endothelial cell basal medium-2 (EBM-
2) with growth factors and supplements (EGM-2) were purchased
from Lonza (Walkersville, MD). AD293 cells, pShuttle vector, pAd-
Easy-1 vector, and pAdEasy titer kit were purchased from Strata-
gene Corp. (La Jolla, CA). The oligonucleotides for ampliﬁcation of
Aurora-B kinase (forward, GGAGAGTAGCAGTGCCTTGG; reverse,
GAAGTGCCGCGTTAAGATGT; 268 bp) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; forward, CGACCACTTTGTCAAGCT-
CA; reverse, AGGGGTCTACATGGCAACTG; 227 bp), and small
interfering RNAs (siRNAs) against Aurora-B (siAurora-B #1, ccaaa-
cugcucaggcauaa; siAurora-B #2, acgcggcacuucacaauug), were ob-
tained from Bioneer Corp., (Daejeon, Republic of Korea). Stealth
negative control RNAi and horseradish peroxidase-conjugated sec-
ondary rabbit polyclonal antibody or mouse antibody were from
Invitrogen Life Technologies Inc., (Carlsbad, CA). Antibodies against
Aurora-B (sc-25426), p53 (sc-126), p16 (sc-468), cyclin A (sc-239),
caspase 3 (sc-7148), and PARP1/2 (sc-7150) were purchased from
Santa Cruz Biotechnology Inc., (Santa Cruz, CA), and antibodies
against phospho-Rb (ser807/811, #9308S) and p21 (#2947S) from
Cell Signaling Technology Inc., (Danvers, MA). A GAPDH antibody
was kindly donated from Dr. KS Kwon from KRIBB (Daejeon,
Republic of Korea). The pRetroSuper-p53sh and pRetroSuper-
p16sh vectors were kindly provided by Dr. R. Agami (Division of
Tumor Biology, The Netherlands Cancer Institute, Amsterdam,
Netherlands).
2.2. Cell culture
HDFs and HUVECs in media were plated at 1  105 cells in a
100 mm culture plate and cultured at 37 C in a 5% CO2 humidiﬁed
incubator. When subcultures reached 80–90% conﬂuence, serial
passaging was performed by trypsinization, and the number of
population doublings (PDs) was monitored for further experi-ments. For experiments, cells were used in either passage 7
(PD < 28) or passage 15 (PD > 55). These are referred to as ‘‘young’’
and ‘‘old’’ cells, respectively.
2.3. Adriamycin treatment
HDFs and HUVECs (PD < 28) were seeded at 1  105 cells in
60 mm dishes and incubated overnight and treated with adriamy-
cin [22].
2.4. Senescence-associated b-galactosidase (SA-b-gal) activity
SA-b-gal activity in cells was measured as described previously
[23]. Cells were counterstained with 1% eosin for 3 min and then
washed two times with PBS. The percentage of blue cells observed
under a light microscope was calculated.
2.5. RNA extraction and reverse transcription-polymerase
chain reaction
RNAs were extracted from cells using Tri-RNA isolation reagent
(Bio Science Technology, Daegu, Korea). RNA (1 lg) was reverse-
transcribed and resulting cDNAs were ampliﬁed. GAPDH primers
were used to standardize the amount of RNA in each sample.
2.6. Real-time quantitative PCR analysis
Real-time quantitative PCR analysis was performed using SYBR
Green PCR master mix (Applied Biosystems Inc., Carlsbad, CA) and
the LightCycler 2.0 Real-Time PCR system (Roche Diagnostic Corp.,
Indianapolis, IN).
2.7. Protein extraction and Western blotting
Cells were lysed with ice-cold RIPA buffer (25 mM Tris–HCl, pH
7.6, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 1 mM Na3VO4, 5 mM NaF, and 1 mM phenylmethyl-
sulfonyl ﬂuoride). Protein concentrations were quantiﬁed by the
bicinchoninic acid method (Thermo Fisher Scientiﬁc, Rockford,
IL). Proteins (30–50 lg) were separated on SDS–polyacrylamide
gels and then transferred to nitrocellulose membranes. Mem-
branes were incubated with one of the speciﬁc antibodies and then
horseradish peroxidase-conjugated goat anti-mouse or goat anti-
rabbit antibodies. The proteins were visualized usingWestern blot-
ting luminol reagent (Santa Cruz Biotechnology Inc., Santa Cruz,
CA) with a LAS-3000 image system.
2.8. Aurora-B cDNA cloning
Aurora-B cDNA was ampliﬁed by PCR using total RNA isolated
from HDFs with Takara HS DNA polymerase (Takara Bio Inc., Shiga,
Japan) and the primers ATGGCCCAGAAGGAGAACTCCTACC and
CGACAGATTGAAGGGCAGAGGG. The PCRproductswere ligated into
pCR2.1-TOPO vector (Invitrogen LifeTechnology Inc., Carlsbad, CA).
Cloned cDNA sequence was veriﬁed by dideoxy DNA sequencing.
2.9. Preparation and transduction of recombinant Aurora-B
adenovirus
Recombinant Aurora-B adenovirus was prepared using AdEasy
system from Stratagene Corp. (La Jolla, CA) according to the man-
ufacturer’s suggestion. Old cells were treated with 2, 4, and 6
MOI (Multiplicity of Infection) of recombinant Aurora-B virus for
24 h. After discarding the media, cells were further incubated for
3 days. Expression levels of p16, p21, PARP1/2, caspase 3, p53,
H.-J. Kim et al. / FEBS Letters 585 (2011) 3569–3576 3571and Aurora-B proteins were conﬁrmed by Western blotting. Cell
proliferation and SA-b-gal activity were measured.
2.10. Transfection of Aurora-B small interfering RNAs (siRNAs)
Two different siRNAs against Aurora-B (10 pmol) were transfec-
ted into young HDFs and HUVECs using Lipofectamine 2000 trans-
fection reagent (Invitrogen Life Technologies Inc., Carlsbad, CA)
according to the manufacturer’s instructions.
2.11. Transfection of p53 or p16 shRNA retroviral vectors
and Aurora-B siRNAs
Cells were transfected with 3 lg of pRetroSuper-p16sh vectors
or pRetroSuper-p53sh vectors using FugeneHD transfection re-
agent (Roche Diagnostic Corp., Indianapolis, IN). After 24 h incuba-
tion, cells were transfected with Aurora-B siRNAs and incubated
for 3, 4 or 6 days. Expression levels of p16, p53, and Aurora-B pro-A
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2.12. Statistical analysis
The results are represented as means ± SD of three independent
experiments. P values for determining statistical signiﬁcance were
calculated using an unpaired two-tailed Student’s t-test.
3. Results
3.1. Down-regulation of Aurora-B during cellular senescence
in human primary cells
In an attempt to screen novel senescence-associated genes in
human primary cells, DNA chip analyseswere performedwith RNAs
extracted from HDFs or HUVECs under replicative senescence. We
found that Aurora-B levels were down-regulated during replicativeHDF
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in HDFs and HUVECswas validated by SA-b-gal staining, altered cell
morphology, and increases in p53, p21 and p16 levels (Fig. 1A and
C). The levels of Aurora-B mRNA were validated to decrease in old
cells by RT-PCR and real-time PCR (Fig. 1B). As expected, the level
of Aurora-B protein was also reduced in old cells (Fig. 1C). In
addition, Aurora-B levels were repressed during stress-induced
premature cellular senescence by adriamycin (Fig. 1D).
3.2. Reversal of cellular senescence by Aurora-B overexpression
in old cells
We transduced old cells with recombinant Aurora-B adenovirus
and observed senescence phenotypes. Up-regulation of Aurora-B
protein levels was conﬁrmed by Western blot analysis (Fig. 2A).
Treatment with Aurora-B adenovirus increased cell proliferation
(Fig. 2B) and decreased SA-b-gal staining (Fig. 2C) in a dose-
dependent manner. In addition, the levels of p53, p21 and p16A HUVEC
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3.3. Induction of cellular senescence by Aurora-B knockdown
To further conﬁrm the role of Aurora-B in cellular senescence,
we knocked down Aurora-B levels in young cells using Aurora-B
siRNAs and examined senescence phenotypes. Down-regulation
of Aurora-B levels was validated by Western blot analysis
(Fig. 3A). Knockdown of Aurora-B levels repressed cell proliferation
(Fig. 3B) and enhanced SA-b-gal staining activity (Fig. 3C). Further-
more, down-regulation of Aurora-B decreased the phosphorylation
of Rb at serine 807 and serine 811 as well as the level of cyclin A,
and increased the levels of p53 and p21 proteins (Fig. 3D). How-
ever, the p16 protein was not detected in Aurora-B siRNA cells
by Western blotting (data not shown). The levels of PARP1/2 and
caspase 3 were not changed by Aurora-B knockdown, suggestingB
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was not mediated through apoptosis.
3.4. Involvement of a p53-dependent pathway in cellular senescence
by Aurora-B knockdown
We tried to identify which tumor suppressor pathway might
play an important role in the regulation of cellular senescence byA
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in SA-b-gal staining, were observed in p16 shRNA cells but not in
p53 shRNA cells (Fig. 4B and C), suggesting that a p53-dependent
pathway might play a crucial role in cellular senescence triggered
by Aurora-B down-regulation.
4. Discussion
The present study clearly showed that Aurora-B kinase plays an
important role in the regulation of cellular senescence in human
primary cells. The roles of Aurora-B in cellular senescence revealed
some controversy. Inhibition of Aurora-B by Aurora-B RNAi or a
chemical inhibitor (hesperadin) is reported to cause polyploidy
and enlarged and ﬂattened cell morphology, similar to cellular
senescence in HeLa cells [25], which is consistent with our results.
In contrast, exogenous introduction of Aurora-B in human BJ ﬁbro-
blast cells and U87MG glioblastoma cells was shown to decrease
cell growth and increase SA-b-gal activity by activation of p53
tumor suppressor [21]. Since increased expression of Aurora-B is
frequently observed in a wide variety of human cancers, some
evidence has suggested that high Aurora-B expression is oncogenic
in vivo, and some Aurora-B inhibitors were proven to be effective as
anticancer drugs in preclinical or clinical trials [14]. It is therefore
reasonable to expect that Aurora-B repression would induce cellu-
lar senescence. Similarly, inhibition of Aurora A by MLN8054, an
inhibitor of Aurora A kinase, induces senescence in human tumor
cells both in vitro and in vivo [19]. However, Aurora A overexpres-
sion induces cellular senescence in mammary gland hyperplastic
tumors developed in p53-deﬁcient mice [18]. Although the incon-
sistency of the effects of Aurora A or B on cellular senescence should
be investigated through a further study, these data suggest that the
alteration of Aurora A or B levels induces mitotic or chromosomal
abnormalities, resulting in senescence phenotypes. In addition to
Aurora A or B, diverse genes involving mitosis and chromosomal
segregation are also known to regulate cellular senescence.
Down-regulation of CENP-A by shRNA was found to cause prema-
ture senescence in human primary ﬁbroblasts through a p53-
dependent pathway [8]. These reports suggest that the dysregula-
tion of mitosis and chromosomal segregation might be one of the
underlying mechanisms of cellular senescence.
One important question is which tumor suppressor pathway
between the p53- and pRb/p16-dependent pathways is involvedin cellular senescence induced by Aurora-B knockdown. We found
that the p53-dependent pathway might be involved in the regula-
tion of cellular senescence induced by Aurora-B down-regulation.
The p53-dependent pathway is activated by DNA damage re-
sponses, such as telomere shortening, inﬂammation, activation of
oncogenes, and irradiation [26,27]. Consistent with our results,
p53 was reported to be required for cellular senescence induced
by alteration of genes involving mitosis and chromosome segrega-
tion, including Aurora-B overexpression [21], CENP-A knockdown
[8], and Aurora A inhibition [19]. In contrast, p53 is not necessary
for cellular senescence induced by Aurora A overexpression [18].
Although growth arrest in senescence is essentially irreversible
by known physiological stimuli, some senescent cells that do not
express p16INK4a can partially recommence cell proliferation after
p53 inactivation [22]. Our ﬁnding that overexpression of Aurora-B
in senescent cells partially reversed senescence phenotypes (Fig. 2)
implies that Aurora-B might regulate cellular senescence via a p53-
dependent pathway.
Taken together, our results imply that during cellular senes-
cence, altered expression of Aurora-B, which plays key roles in
the progression from mitotic entry to cytokinesis, might cause
defective mitosis, resulting in growth arrest and cellular senes-
cence in human primary cells. Consistent with other reports
[6,8], senescence induced by altered Aurora-B seems to contribute
to tissue homeostasis, tissue and organismal aging, and age-related
pathologies. Furthermore, it seems to play important roles in the
prevention of emerging cells with abnormal chromosomes as well
as the protection of cellular transformation against chromosomal
abnormalities [8].
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